Developer and provider of RNA interference ( RNAi ) technology designed to treat liver diseases. Ribo Life Science is based in Suzhou, China and was founded in 2007. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $1.2 billion (Jan 2026). It has raised $285 million.
Last price · $/share
—
Implied valuation
$1.2B
Total raised
$285.3M
Last round
—
Cap table — not yet on record
Ribo Life Science's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Ribo Life Science with a free account
·The complete investor list: 12 names
·Watch Ribo Life Science: the Monday email on marks, rounds and moves
